all Amy Wagers stories

GlaxoSmithKline and Harvard Stem Cell Institute announce major collaboration agreement

404132862 — Mon, 21 Jul 2008 15:00:05 -0400

GlaxoSmithKline (GSK) and the Harvard Stem Cell Institute (HSCI) today announced that they have entered into a five-year, $25 million-plus collaborative agreement to build a unique alliance in stem cell science to hasten the development of treatments and cures for a range of diseases.

Stem cells used to treat muscular dystrophy in mice

404132862 — Fri, 11 Jul 2008 10:45:11 -0400

Harvard Stem Cell Institute researchers at the Joslin Diabetes Center have for the first time demonstrated that transplanted muscle stem cells can both improve muscle function in mice with a form of muscular dystrophy and replenish the stem cell population for use in the repair of future muscle injuries.

Amy Wagers - focusing on stem cell biology

404132862 — Fri, 11 Jul 2008 09:45:39 -0400

Twenty minutes after her weekly lab meeting is scheduled to begin, Amy Wagers rushes into a conference room on the fourth floor of the Joslin Diabetes Center, where her lab team sits, chatting around a long oval table.

“Sorry I’m late,” she calls out, closing the door behind her. “Oh good, the food’s here!"

Grabbing half a sandwich and a pickle off a catered tray, she simultaneously grabs a seat and motions for her team to begin its presentations. Lights out.

In the darkened room, all eyes turn to the illuminated white screen. There, in all its monochromic splendor, glows an enlarged image of a blood-forming hematopoietic stem cell.